Curogen Taps Industry Veteran Arvind Sood to Establish and Grow U.S. Business; Expands Global Board of Directors

SEOUL, South Korea and BEVERLY HILLS, Calif., June 2, 2025 /PRNewswire/ --  Curogen, one of South Korea's leading biotechnology companies focused on nanotechnology-based treatments for autoimmune diseases, today announced a series of strategic appointments that strengthen its global leadership team and board of directors. These moves position Curogen to accelerate its research and development efforts and expand its footprint in the U.S. and global markets.

Arvind Sood, MBA, will initially consult and advise Curogen on establishing a U.S. organization and will assume the title of Global Chief Operating Officer upon its launch. Sood brings decades of experience in the global pharmaceutical sector, having most recently served as President, US Operations, Innate Pharma SA, a France-based clinical-stage biotech company. Previously, he was a Vice President for over two decades at California-based Amgen, Inc, a leading biotechnology company.

"Curogen is developing novel combination autoimmune treatments and exploring new pathways to target autoimmune diseases with oral drugs," said Sood. "I'm excited to join the company and help lead the way in transforming the treatment of autoimmune diseases."

"We are thrilled to welcome Arvind and our new Board members to Curogen," said Chang-Woo Lee, Chief Executive Officer of Curogen. "Their combined expertise will help propel Curogen's groundbreaking nanotechnologies into the global marketplace, advancing our mission to bring transformative therapies for autoimmune diseases to patients in need, as well as fundamentally improving the treatment of autoimmune diseases."

To support its U.S. initiative, Curogen has also expanded its Board of Directors with seven distinguished leaders:

• Chang-Woo Lee, Ph.D., Founder and Chief Executive Officer of Curogen. Professor Lee brings over two decades of experience in medical research across academia and the biotechnology industry. He forms the scientific foundation for Curogen towards advancing next-generation innovations in autoimmune diseases;
• Allan Gibofsky, M.D., Professor of Medicine at Weill Cornell Medical College and Attending Rheumatologist at the Hospital for Special Surgery, where he co-directs the Clinic for Inflammatory Arthritis and Biologic Therapy;
• Craig Gordon, M.D., Founder and Chief Executive Officer of GordonMD Global Investments®. Dr. Gordon's extensive experience in global biopharmaceutical investing is ideally suited to drive Curogen's strategic growth in the United States;
• Doug Manion, M.D., FRCP (C), Chief Executive Officer and Director, Flare Therapeutics, a pharmaceutical company focused on targeting oncologic diseases and has more than two decades of company building and drug development expertise;
• Jaeyeol An, Ph.D., Managing Director at Partners Investments, oversees its dedicated life sciences fund, bringing extensive global investment experience with a strong focus on bridging Korean biotechs innovation with the US market, serving on the boards of several Korean and US biotech companies, contributing strategic insight and cross-border partnership expertise;
• Kiho Choi, MBA, Professor at the Global Entrepreneurship Graduate School at Sungkyunkwan University, and former Country Manager at Sanford Research Institute International and Managing Director at Intel Capital's Strategic Investment Group; and
• Sungjune Hong, LLM, MBA, CEO of Genexine, with prior leadership roles including CFO at Handok, Phillip Morris, Schneider Electric, and Nike Korea, as well as President and COO of ROKIT Healthcare.

"Curogen has transformed from a pioneering South Korean biotech into a world-class R&D company," said Dr. Craig Gordon. "I am excited to help guide its U.S. expansion and support Curagen's innovative product pipeline as it takes a prominent place in the global biopharmaceutical landscape."

About Curogen

Curogen Technology is a preclinical biotechnology company focused on discovering and developing novel therapeutic targets and combinations to address autoimmune diseases. Its pipeline includes innovative small molecules and multi-specific TRAP proteins targeting conditions such as inflammatory bowel disease, hidradenitis suppurativa, and other diseases with high unmet need.

About GordonMD Global Investments® LP

Founded in 2021 by Craig Gordon, M.D., GordonMD Global Investments® LP is a leading investment firm managing both private and public funds focused on biopharmaceutical companies. With a focus on differentiated investment opportunities, the firm operates across the U.S., Europe, and Asia.

SOURCE GordonMD Global Investments®